<DOC>
	<DOCNO>NCT02432261</DOCNO>
	<brief_summary>This prospective , randomize , double-blinded , two-center trial evaluate gonadotropin suppressive activity transdermal treatment combine NES/T gel , T gel alone , 28 day .</brief_summary>
	<brief_title>Evaluate Pharmacokinetics Gonadotropin Suppression Nestorone®-Testosterone ( NES/T ) Combination Gel Men</brief_title>
	<detailed_description>A total 45 subject enrol randomized 2:1 ratio one two treatment group . A description group follow : - Group 1 ( 30 subject ) : 5.0 mL 1.62 % combine gel ( contain 8.3 mg NES + 62.5 mg T ) apply day arm shoulder - Group 2 ( 15 subject ) : 4.4 mL 1.62 % AndrogelTM ( contain 62.7 mg T ) apply day arm shoulder The total duration treatment 28 day follow 72 hour sample period ass half-life recovery period least 28 day , point subject return clinic end study visit .</detailed_description>
	<mesh_term>ST 1435</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>1 . Male volunteer good health confirm physical examination , medical history , clinical laboratory test blood urine time screening ; 2 . 18 50 year age ; 3 . BMI &lt; 33 calculated weight Kg/ ( height cm ) 2 ; 4 . No history hormonal therapy use last six month prior first screen visit ; 5 . Subject agree use recognize effective method contraception partner ( i.e . minimum , condom male partner effective contraception female partner ) course study treatment recovery phase ; 6 . In opinion investigator , subject able comply protocol , understand sign inform consent HIPAA form ; 7 . Does meet exclusion criterion . 8 . Sperm concentration ≥ 15 million sperm per milliliter ejaculate . 1 . Men participate another clinical trial involve investigational drug within last 30 day prior first screen visit ; 2 . Men live catchment 's area clinic within reasonable distance site ; 3 . Clinically significant abnormal physical finding screen ; 4 . Elevated PSA ( level ≥ 4 ng/mL ) , accord local laboratory normal value ; 5 . Abnormal serum chemistry value , accord local laboratory normal value indicate liver kidney dysfunction may consider clinically significant ; 6 . Use androgens body building substance within 6 month first screen visit ; 7 . Diastolic blood pressure ( DBP ) &gt; 80 and/or Systolic ( SBP ) &gt; 130 mm Hg ; 8 . EKG abnormal clinically significant QTC level longer 450msec ; 9 . History hypertension , include hypertension control treatment ; 10 . Known history primary testicular disease disorder hypothalamicpituitary axis ; 11 . Known hypersensitivity progestins androgen ; 12 . Family personal history venous thromboembolism ; 13 . Benign malignant liver tumor ; active liver disease ; 14 . Known history reproductive dysfunction include vasectomy infertility ; 15 . Known history cardiovascular , renal , hepatic prostatic disease ; 16 . A serious systemic disease diabetes mellitus morbid obesity ( body weight great 120 % ideal body weight BMI limitation ) ; 17 . Known suspected alcoholism drug abuse may affect metabolism/transformation steroid hormone study treatment compliance ; 18 . Known dermatitis severe skin disorder ; 19 . Moderate severe depression determine PHQ9 score &gt; 15 ; 20 . Partner known pregnant ; 21 . Known suspect breast prostate cancer ; 22 . Allergic ingredient testosterone/nestorone gel , include alcohol ; 23 . Known history untreated sleep apnea ; 24. International Prostate Symptom Score ( IPSS ) great equal 15 .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>spermatogenesis</keyword>
	<keyword>androgen</keyword>
	<keyword>male contraception</keyword>
</DOC>